IMR Press / FBS / Volume 7 / Issue 2 / DOI: 10.2741/S441

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Anaplastic lymphoma kinase: activating mechanisms and signaling pathways
Show Less
1 Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy
2 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10021, USA
3 Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy
4 Department of Pathology and NYU Cancer Center, New York University School of Medicine, New York, NY, 10016 USA
5 European Research Initiative on ALK-related malignancies (ERIA)

*Author to whom correspondence should be addressed.


Front. Biosci. (Schol Ed) 2015, 7(2), 283–305;
Published: 1 June 2015

The discovery of Anaplastic Lymphoma Kinase (ALK) by Stephan Morris and colleagues twenty years ago has led to an unprecedented opportunity and provided the basis for a novel and clinically powerful stratification of human cancers. The molecular and biological characterization of ALK and the recognition of alternative mechanisms of activation of the tyrosine kinase receptors have then set the basis for the development and the subsequent application of selective small molecules. These achievements have fostered a new era in oncology, and the result of this new avenue has drastically changed the expectation of many cancer patients. Here we review the mechanisms of ALK activation and the modalities that drive ALK pathogenesis.

Anaplastic Lymphoma Kinase
Anaplastic Large Cell Lymphoma
Signaling pathways
Oncogenic addiction
Back to top